RepliCel Life Sciences Inc. (REPCF)
USD 0.0
(0.0%)
USD 0.0
(0.0%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | -1.38 Million CAD | -626.55% |
| 2022 | -735.68 Thousand CAD | 93.99% |
| 2021 | -3.17 Million CAD | -177.45% |
| 2020 | -1.34 Million CAD | 60.33% |
| 2019 | -2.92 Million CAD | -6.43% |
| 2018 | -2.69 Million CAD | 54.58% |
| 2017 | - CAD | -38.63% |
| 2016 | - CAD | 14.52% |
| 2015 | -5.02 Million CAD | 3.28% |
| 2014 | -5.19 Million CAD | -1436.07% |
| 2013 | 540.13 Thousand CAD | 106.98% |
| 2012 | - CAD | -48.94% |
| 2011 | -3.71 Million CAD | -56.25% |
| 2010 | - CAD | -567.53% |
| 2009 | -359.1 Thousand CAD | -256.05% |
| 2008 | -100.85 Thousand CAD | 28.88% |
| 2007 | -141.8 Thousand CAD | 81.1% |
| 2006 | -750.22 Thousand CAD | -204.68% |
| 2005 | -246.22 Thousand CAD | -18.95% |
| 2004 | -206.99 Thousand CAD | -125.59% |
| 2003 | -91.75 Thousand CAD | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q1 | -126.09 Thousand CAD | 58.29% |
| 2024 Q2 | -65.42 Thousand CAD | 48.11% |
| 2023 Q3 | -671.15 Thousand CAD | -32.81% |
| 2023 Q1 | -727.09 Thousand CAD | -127.62% |
| 2023 FY | - CAD | -626.54% |
| 2023 Q2 | -505.36 Thousand CAD | 30.5% |
| 2023 Q4 | -302.31 Thousand CAD | 54.96% |
| 2022 Q2 | -1.03 Million CAD | -35.15% |
| 2022 FY | - CAD | 93.99% |
| 2022 Q1 | -764.89 Thousand CAD | 65.96% |
| 2022 Q4 | 2.63 Million CAD | 356.98% |
| 2022 Q3 | -1.02 Million CAD | 0.91% |
| 2021 Q1 | 340.89 Thousand CAD | 255.39% |
| 2021 Q3 | -515.33 Thousand CAD | 31.21% |
| 2021 Q4 | -2.24 Million CAD | -336.04% |
| 2021 Q2 | -749.18 Thousand CAD | -319.77% |
| 2021 FY | - CAD | -177.45% |
| 2020 Q4 | -219.38 Thousand CAD | 53.41% |
| 2020 Q2 | -248.34 Thousand CAD | 25.41% |
| 2020 Q1 | -332.92 Thousand CAD | 45.99% |
| 2020 FY | - CAD | 60.33% |
| 2020 Q3 | -470.88 Thousand CAD | -89.61% |
| 2019 Q3 | -546.6 Thousand CAD | 41.05% |
| 2019 Q2 | -927.24 Thousand CAD | 9.34% |
| 2019 FY | - CAD | -6.43% |
| 2019 Q4 | -616.41 Thousand CAD | -12.77% |
| 2019 Q1 | -1.02 Million CAD | -16.68% |
| 2018 FY | - CAD | 54.58% |
| 2018 Q2 | -580.59 Thousand CAD | -21.1% |
| 2018 Q1 | -479.44 Thousand CAD | 12.75% |
| 2018 Q4 | -876.57 Thousand CAD | -13.86% |
| 2018 Q3 | -769.86 Thousand CAD | -32.6% |
| 2017 Q4 | -549.53 Thousand CAD | 55.6% |
| 2017 Q3 | -1.23 Million CAD | 50.21% |
| 2017 Q2 | -2.48 Million CAD | -47.48% |
| 2017 Q1 | -1.68 Million CAD | 4.35% |
| 2017 FY | - CAD | -38.63% |
| 2016 Q2 | -794.44 Thousand CAD | 28.92% |
| 2016 Q4 | -1.76 Million CAD | -182.46% |
| 2016 FY | - CAD | 14.52% |
| 2016 Q1 | -1.11 Million CAD | 13.7% |
| 2016 Q3 | -623.85 Thousand CAD | 21.47% |
| 2015 FY | - CAD | 3.28% |
| 2015 Q4 | -1.29 Million CAD | -10.63% |
| 2015 Q3 | -1.17 Million CAD | 14.21% |
| 2015 Q2 | -1.36 Million CAD | -13.98% |
| 2015 Q1 | -1.19 Million CAD | 14.8% |
| 2014 Q2 | -1.32 Million CAD | -13.58% |
| 2014 Q3 | -1.29 Million CAD | 2.38% |
| 2014 Q1 | -1.16 Million CAD | 29.32% |
| 2014 FY | - CAD | -1436.07% |
| 2014 Q4 | -1.4 Million CAD | -8.42% |
| 2013 FY | - CAD | 106.98% |
| 2013 Q4 | -1.65 Million CAD | -142.91% |
| 2013 Q2 | -1.17 Million CAD | -85.5% |
| 2013 Q3 | 3.85 Million CAD | 427.52% |
| 2013 Q1 | -634.43 Thousand CAD | 44.9% |
| 2012 Q1 | -724.04 Thousand CAD | 3.7% |
| 2012 Q2 | -1.83 Million CAD | -154.05% |
| 2012 Q4 | -1.15 Million CAD | 28.72% |
| 2012 Q3 | -1.61 Million CAD | 12.18% |
| 2012 FY | - CAD | -48.94% |
| 2011 Q3 | -1.04 Million CAD | 1.67% |
| 2011 Q1 | -892.73 Thousand CAD | 61.1% |
| 2011 Q2 | -1.05 Million CAD | -18.7% |
| 2011 Q4 | -751.82 Thousand CAD | 27.85% |
| 2011 FY | - CAD | -56.25% |
| 2010 Q3 | -114.5 Thousand CAD | 12.88% |
| 2010 Q2 | -131.44 Thousand CAD | -724.8% |
| 2010 Q1 | -15.93 Thousand CAD | 66.9% |
| 2010 Q4 | -2.29 Million CAD | -1904.49% |
| 2010 FY | - CAD | -567.53% |
| 2009 Q3 | -31.96 Thousand CAD | 86.85% |
| 2009 Q4 | -48.14 Thousand CAD | -50.63% |
| 2009 Q2 | -243.13 Thousand CAD | -464.98% |
| 2009 Q1 | -43.03 Thousand CAD | -909.52% |
| 2009 FY | - CAD | -256.05% |
| 2008 Q1 | -34.39 Thousand CAD | -329.3% |
| 2008 Q4 | -4262.81 CAD | 88.09% |
| 2008 Q3 | -35.77 Thousand CAD | -33.59% |
| 2008 Q2 | -26.78 Thousand CAD | 22.15% |
| 2008 FY | - CAD | 28.88% |
| 2007 Q3 | -144.1 Thousand CAD | -75.74% |
| 2007 Q1 | 69.06 Thousand CAD | 124.81% |
| 2007 FY | - CAD | 81.1% |
| 2007 Q4 | 15 Thousand CAD | 110.41% |
| 2007 Q2 | -81.99 Thousand CAD | -218.72% |
| 2006 Q3 | -90.54 Thousand CAD | 74.48% |
| 2006 Q1 | -26.46 Thousand CAD | 12.86% |
| 2006 FY | - CAD | -204.68% |
| 2006 Q4 | -278.35 Thousand CAD | -207.44% |
| 2006 Q2 | -354.78 Thousand CAD | -1240.43% |
| 2005 Q3 | -22.56 Thousand CAD | 71.79% |
| 2005 FY | - CAD | -18.95% |
| 2005 Q2 | -79.98 Thousand CAD | 29.22% |
| 2005 Q1 | -113 Thousand CAD | -119.14% |
| 2005 Q4 | -30.37 Thousand CAD | -34.63% |
| 2004 Q1 | -19.27 Thousand CAD | 0.0% |
| 2004 Q2 | -323.48 Thousand CAD | -1578.39% |
| 2004 Q4 | 590.46 Thousand CAD | 261.77% |
| 2004 FY | - CAD | -125.59% |
| 2004 Q3 | -364.99 Thousand CAD | -12.83% |
| 2003 Q2 | - USD | 0.0% |
| 2003 FY | - CAD | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Burzynski Research Institute, Inc. | - USD | Infinity% |
| Santhera Pharmaceuticals Holding AG | 94.03 Million USD | 101.473% |
| Neon Bloom, Inc. | -632.4 Thousand USD | -118.971% |
| Nascent Biotech, Inc. | 527.43 Thousand USD | 362.552% |
| Qrons Inc. | -40.08 Thousand USD | -3354.964% |
| Regen BioPharma, Inc. | -936.94 Thousand USD | -47.797% |
| Evofem Biosciences, Inc. | -17.37 Million USD | 92.028% |
| BioStem Technologies, Inc. | -7.55 Million USD | 81.667% |
| Skye Bioscience, Inc. | -13.54 Million USD | 89.778% |
| ProtoKinetix, Incorporated | -367.22 Thousand USD | -277.098% |
| Rebus Holdings, Inc. | -951 Thousand USD | -45.613% |
| CSL Limited | 4.78 Billion USD | 100.029% |
| Northwest Biotherapeutics, Inc. | -55.33 Million USD | 97.498% |
| Capstone Therapeutics Corp. | -1.74 Million USD | 20.869% |
| Acro Biomedical Co., Ltd. | -15.86 Million USD | 91.274% |
| Adynxx, Inc. | - USD | Infinity% |
| Arch Therapeutics, Inc. | -3.88 Million USD | 64.349% |
| Eiger BioPharmaceuticals, Inc. | -71.03 Million USD | 98.051% |
| Nanobac Pharmaceuticals, Incorporated | -5.92 Million USD | 76.644% |
| Institute of Biomedical Research Corp. | -239.15 Thousand USD | -479.044% |
| SQZ Biotechnologies Company | -64.14 Million USD | 97.841% |
| Intellipharmaceutics International Inc. | -2.64 Million USD | 47.634% |
| Propanc Biopharma, Inc. | -1.53 Million USD | 9.848% |
| Mesoblast Limited | -62.38 Million USD | 97.78% |
| Marizyme, Inc. | -34.28 Million USD | 95.961% |
| Genus plc | 73.7 Million USD | 101.879% |
| VioQuest Pharmaceuticals, Inc. | -6.61 Million USD | 79.055% |
| Pharming Group N.V. | 9.87 Million USD | 114.02% |
| Therapeutic Solutions International, Inc. | -1.48 Million USD | 6.9% |
| CNBX Pharmaceuticals Inc. | -3.54 Million USD | 60.959% |
| Nymox Pharmaceutical Corporation | -8.77 Million USD | 84.214% |
| ContraFect Corporation | -64.99 Million USD | 97.87% |
| PsyBio Therapeutics Corp. | -4.52 Million USD | 69.405% |
| Sienna Biopharmaceuticals, Inc. | - USD | Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | -1.4 Million USD | 1.214% |
| IMV Inc. | -35.52 Million USD | 96.102% |
| AXIM Biotechnologies, Inc. | -2.32 Million USD | 40.409% |
| MultiCell Technologies, Inc. | -518.04 Thousand USD | -167.309% |
| ONE Bio Corp. | 13.61 Million USD | 110.172% |
| Accustem Sciences Inc. | -3.74 Million USD | 63.037% |
| RVL Pharmaceuticals plc | -48.22 Million USD | 97.129% |
| Arno Therapeutics, Inc. | - USD | Infinity% |
| EV Biologics, Inc. | -1.26 Million USD | -9.285% |
| Q BioMed Inc. | -617.62 Thousand USD | -124.21% |
| Emmaus Life Sciences, Inc. | 3.57 Million USD | 138.768% |
| Mosaic ImmunoEngineering Inc. | -2.28 Million USD | 39.383% |
| Biomind Labs Inc. | -1.03 Million USD | -33.854% |
| American Oriental Bioengineering, Inc. | -39.63 Million USD | 96.506% |
| Provectus Biopharmaceuticals, Inc. | -2.89 Million USD | 52.122% |
| TetraLogic Pharmaceuticals Corporation | - USD | Infinity% |
| Oncotelic Therapeutics, Inc. | -7.16 Million USD | 80.663% |
| GlobeStar Therapeutics Corporation | 6724.00 USD | 20694.646% |
| THC Farmaceuticals, Inc. | -25 Thousand USD | -5439.136% |
| Curative Biotechnology, Inc. | -2.5 Million USD | 44.652% |
| GB Sciences, Inc. | -1.41 Million USD | 2.472% |
| Alpha Cognition Inc. | -9.7 Million USD | 85.732% |
| HST Global, Inc. | -5303.00 USD | -26013.219% |
| Wesana Health Holdings Inc. | -2.05 Million USD | 32.679% |
| Halberd Corporation | -74.27 Thousand USD | -1764.301% |
| Enzolytics Inc. | -2.12 Million USD | 34.742% |
| Agentix Corp. | -1.37 Million USD | -0.95% |
| Resverlogix Corp. | -11.74 Million USD | 88.207% |
| Nuo Therapeutics, Inc. | -3.06 Million USD | 54.79% |
| MetaStat, Inc. | - USD | Infinity% |
| argenx SE | -216.02 Million USD | 99.359% |
| Enzon Pharmaceuticals, Inc. | 1.21 Million USD | 213.787% |
| Endonovo Therapeutics, Inc. | 8.85 Million USD | 115.641% |
| RespireRx Pharmaceuticals Inc. | -1.49 Million USD | 7.614% |
| GeneThera, Inc. | - USD | Infinity% |
| Inhibitor Therapeutics, Inc. | 378.84 Thousand USD | 465.529% |
| AVAX Technologies, Inc. | -6.11 Million USD | 77.346% |
| Zenith Capital Corp. | -8.6 Million USD | 83.909% |
| Genscript Biotech Corporation | -248.71 Million USD | 99.443% |
| Ember Therapeutics, Inc. | -17.42 Thousand USD | -7848.935% |
| Anthera Pharmaceuticals, Inc. | - USD | Infinity% |
| Sigyn Therapeutics, Inc. | -2.44 Million USD | 43.396% |
| WPD Pharmaceuticals Inc. | -176.02 Thousand USD | -686.7% |
| Cotinga Pharmaceuticals Inc. | -1.92 Million USD | 27.91% |
| Kadimastem Ltd | -2.62 Million USD | 47.234% |
| Helix BioMedix, Inc. | -1.04 Million USD | -32.349% |
| VitaSpring Biomedical Co. Ltd. | - USD | Infinity% |
| Oncology Pharma Inc. | - USD | Infinity% |
| Reve Technologies, Inc. | -181.08 Thousand USD | -664.702% |
| LadRx Corporation | 412.28 Thousand USD | 435.882% |
| Cell Source, Inc. | -4.27 Million USD | 67.589% |
| Regen BioPharma, Inc. | 1.46 Million USD | 194.463% |
| NovAccess Global Inc. | -1.03 Million USD | -33.822% |
| Affymax, Inc. | -14.29 Million USD | 90.313% |
| Itoco Inc. | -1.86 Million USD | 25.908% |
| Rasna Therapeutics, Inc. | -379.62 Thousand USD | -264.782% |
| Pathfinder Cell Therapy, Inc. | -1.11 Million USD | -24.085% |
| Mobile Lads Corp. | -2.24 Million USD | 38.211% |
| CytoDyn Inc. | -18.02 Million USD | 92.319% |
| Claritas Pharmaceuticals, Inc. | - USD | Infinity% |
| NDT Pharmaceuticals Inc. | -79.02 Thousand USD | -1652.248% |
| NanoSphere Health Sciences Inc. | -12.22 Thousand USD | -11223.771% |
| Alseres Pharmaceuticals, Inc. | -485.67 Thousand USD | -185.124% |
| SYBLEU INC | -141.57 Thousand USD | -878.155% |
| Advanced Proteome Therapeutics Corporation | - USD | Infinity% |
| ImmunoCellular Therapeutics, Ltd. | -1.06 Million USD | -30.393% |
| International Stem Cell Corporation | 202 Thousand USD | 785.537% |
| Bioxytran, Inc. | -3.82 Million USD | 63.751% |
| GlobeImmune, Inc. | - USD | Infinity% |
| Predictive Technology Group, Inc. | - USD | Infinity% |
| ProText Mobility, Inc. | -52.64 Thousand USD | -2530.669% |
| Cardax, Inc. | - USD | Infinity% |
| VG Life Sciences Inc. | -2.46 Million USD | 43.752% |
| Kaleido Biosciences, Inc. | - USD | Infinity% |
| Advaxis, Inc. | -35.86 Million USD | 96.139% |
| Adhera Therapeutics, Inc. | - USD | Infinity% |
| RenovaCare, Inc. | - USD | Infinity% |
| Regnum Corp. | -45 Thousand USD | -2977.298% |
| Innovation Pharmaceuticals Inc. | -2.73 Million USD | 49.424% |
| Neutra Corp. | -181.24 Thousand USD | -664.031% |
| Windtree Therapeutics, Inc. | -20.15 Million USD | 93.131% |
| PureTech Health plc | -11.62 Million USD | 88.09% |
| Coeptis Therapeutics, Inc. | -20.15 Million USD | 93.13% |
| IXICO plc | -707 Thousand USD | -95.868% |
| IntelGenx Technologies Corp. | -7.68 Million USD | 81.981% |
| Gelesis Holdings, Inc. | -48.34 Million USD | 97.136% |
| CSL Limited | 4.73 Billion USD | 100.029% |
| Cellectis S.A. | -92.63 Million USD | 98.505% |